Ctla-4
Entity.
- Evidence
- 30 documents · 14 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 29 Apr 2026, last seen 7 Oct 2026
- Measured
- 23% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-10-07 · Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-10-06 · Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial (opens the source in a new tab)
- Financial Post · 2026-10-04 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-02 · Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-01 · Molecular profiling and prognostic significance of gastric cancer subtypes based on extracellular vesicle-related characteristics (opens the source in a new tab)
- AllSci News · 2026-09-30 · Vividion’s WRN inhibitor shows first clinical proof of synthetic lethality in MSI-high cancers (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-30 · Editorial: Novel theragnostic approaches in thoracic malignancies (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-29 · Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-29 · Case Report: Immune checkpoint inhibitor–induced hypophysitis presenting as acute paralytic ileus mimicking mechanical bowel obstruction in a patient affec… (opens the source in a new tab)
- Clinical Trials Arena · 2026-09-28 · Akeso begins Phase III study of cadonilimab for gastric cancer (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-09-28 · Akeso Enrolls First Patient in Phase III Trial of Cadonilimab vs Nivolumab for Gastric Cancer (opens the source in a new tab)
- Fierce Biotech · 2026-09-09 · Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2 (opens the source in a new tab)